Vertex Pharmaceuticals Incorpor (VRTX) Stock Analysis
Healthcare · Biotechnology
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell... Read more
TrendMatrix rates Vertex Pharmaceuticals Incorpor (VRTX) as Sell with moderate confidence. The stock trades at $456.40 with +1.6% upside to the $465.57 price target. Overall score: 5.4/10 across 10 analysis dimensions. Reward/risk ratio: 0.2:1.
Passes 2/4 gates (clean insider activity, no SEC red flags). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Vertex Pharmaceuticals Incorpor (VRTX) as Sell with moderate confidence. Score 5.4/10.
Take-profit target: $465.57 (+1.6% upside). Reward/risk ratio: 0.2:1. Stop-loss: $427.96.
Analyst target reached - limited upside remaining; Consecutive earnings misses (2); Negative momentum.
Vertex Pharmaceuticals Incorpor trades at a P/E of 29.3 (forward 20.5). TrendMatrix value score: 4.2/10. Verdict: Sell.
39 analysts cover VRTX with a consensus score of 4.1/5. Average price target: $548.
What does Vertex Pharmaceuticals Incorpor do?Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and...
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.